RAG 18
Alternative Names: RAG-18Latest Information Update: 26 Aug 2024
At a glance
- Originator Ractigen Therapeutics
- Class Oligonucleotides; RNA
- Mechanism of Action Gene expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 22 Aug 2024 RAG 18 receives Orphan Drug status for Duchenne muscular dystrophy in USA
- 25 Jul 2024 US FDA grants Rare Pediatric Disease Designation (RPDD) to RAG 18 for Duchenne Muscular Dystrophy
- 02 Nov 2023 Ractigen Therapeutics plans to initiate a phase I trial for Duchenne muscular dystrophy (Parenteral), by early 2025